In an extraordinary move, the FDA has withdrawn draft guidance for biosimilars after receiving public comments and 1 citizen petition. But what makes the FDA about-face on biosimilar evaluation so monumental is that it was the direct result of the citizen petition. Filed by one man: Sarfaraz Niazi.
from Forbes – Tech https://ift.tt/2AaVTMW
via IFTTT